#Immunotherapeutics for #hememalignancy. Stem cell mobilization. #CARTcell #GvHD #CRISPR #CytokineReleaseSyndrome @wustlmed @sitemancenter
Joined January 2021
- Tweets58
- Following13
- Followers588
- Likes24
John F. DiPersio Lab retweeted
The Pachynski Lab is looking to hire!
Leukocyte trafficking, tumor immunology, and basic/translational projects with a focus on prostate cancer.
Please RT!
sites.wustl.edu/pachynskilab…
#postdocjobs @PCF_Science @WUSTLdbbs @WUSTLImmuno @ACS_Research @WUSTLmed
John F. DiPersio Lab retweeted
Amazing opportunities to develop cutting edge #neoantigen vaccine trials (@GavinGpdunn @LabFehniger @Pachynski_Lab @malachigriffith @chrisamiller), #ctdna studies (@aadel_chaudhuri @ChrisMaher_Lab) and novel #ProstateCancer treatments (@MReimersMD @uropro)!
Want to know what we are up to @SitemanCenter in St. Louis?
@WUSTLmed @WUDeptMedicine @WashUHeme @RPachynski @mpndoc @dgermain21
siteman.wustl.edu/wp-content…
John F. DiPersio Lab retweeted
Siteman has been ranked No. 1 in Missouri, No. 1 in St. Louis and among the top 1% of cancer centers nationally by U.S. News & World Report.
Learn more: ow.ly/1EVL50FEYP6.
John F. DiPersio Lab retweeted
Spectacular to work with Wugen to expand the impact of memory NK cells! @WUSTLmed @MACattackLab @DiPersioLab
A stealthy startup is leveraging natural killer cells with 'memory-like' abilities to go after blood cancer and beyond - endpts.com/a-stealthy-startu…
John F. DiPersio Lab retweeted
Spring in #stlouis…not too shabby 🎉 Forest Park right across the street from @SitemanCenter @WUSTLmed…great opportunities! @LabFehniger @NathanSinghLab1 @DiPersioLab @ChrisMaher_Lab @aadel_chaudhuri
John F. DiPersio Lab retweeted
So wonderful to have our 100th CAR-T cell patient treated @SitemanCenter be my patient "Mr. Ronnie McCART" Destiny? Thanks to everyone on the team who makes these cutting-edge cell therapy happen for our patients! @WUSTLmed
m.facebook.com/story.php?sto…
John F. DiPersio Lab retweeted
Is tonic CAR signaling always bad? Maybe not! Check out our study out today in @NatureMedicine. Based on clinical trial data, we found that antigen-independent signaling of 41BB-based CARs enhances anti-leukemic activity by priming T cells for effector function. #CART (1/3)
John F. DiPersio Lab retweeted
CAR T cells approved for follicular lymphoma
gilead.com/news-and-press/pr…
John F. DiPersio Lab retweeted
We are hiring! If you know anyone interested in using genomics and structural biology to improve cell-based immunotherapies, please send them to jobs.wustl.edu (search posting 50876). Looking for people at all experience levels! #CARTcells #tcellrx @WUSTLmed
John F. DiPersio Lab retweeted
Medical oncologist @DiPersioLab recently got his final dose of the #COVID19vaccine. “We recommend that cancer patients who have completed their treatment get the vaccine, too.” Read the @SitemanCenter’s vaccine Q&A at siteman.wustl.edu/should-can…
